Open Clinical Trials

Below you can find information about clinical trials currently open at our three sites:

  • Cork University Hospital (CUH)
  • Bon Secours Hospital Cork (BSH)
  • University Hospital Waterford (UHW)

If you have questions or queries, please contact the relevant research nurse assigned to each site.

Open Clinical Trials

If you are interested in taking part in a trial, we strongly encourage you to discuss it with your consulting medical team.

Information Last Updated: 28 June 2024

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
Ember-4 Study to
compare a study drug called Imlunestrant versus standard hormonal therapy in participants with early breast cancer that is
oestrogen receptor positive (ER+) and human epidermal
receptor 2 negative (HER2-) 		 Participants with early breast cancer that is
oestrogen receptor positive (ER+) and human epidermal
receptor 2 negative (HER2-) and high-risk. Participants must have already taken hormonal therapy for two
to five years 		 CUH

BSH

 Click
here
Shamrock
study 		 Study to
assess the effectiveness of a study drug called trastuzumab deruxtecan (T-DXd)  before definite surgery in patients with early stage locally advanced HER2
positive breast cancer 		 Patient
with newly diagnosed early stage HER2-positive breast cancer with tumour size larger than
2cm 		 CUH Click
here
Proteomics
study 		 Breast
Cancer Proteomics and Molecular Heterogeneity 		 All newly
diagnosed participants with blood
cancer, recurrent and stage IV
metastatic breast cancer patient 		 CUH Click
here
EXPERT Study aims to determine if a genomic test (examining specific genes)
on breast cancer tissue can identify women who can safely skip radiation therapy due to their
low risk of cancer
recurrence. 		 Female participants with
HER2 negative early-stage breast cancer and menopausal status diagnosed with hormone
receptor-positive  		 CUH Click
here

 

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
ADEPPT Study to assess the effectiveness of a study drug called adagrasib in patients in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2)  Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2)  or elderly (≥70 years) (ECOG PS=0-1)   UHW Click
here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
DESTINY-Gastric04 Study of Trastuzumab Deruxtecan in Subjects with HER2-Positive Metastatic and/or Unresectable
Gastric or Gastro-Oesophageal Junction (GEJ) Adenocarcinoma 		 HER2-Positive Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen  CUH Click
here
MOUNTAINEER-03  Study comparing a drug called Tucatinib in Combination with Trastuzumab and mFOLFOX6 Versus mFOLFOX6 given with or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer  Locally advanced unresectable HER2 Positive colorectal
cancer  
UHW
BSH
CUH
Click
here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
BO42843
(IMvigor 011)		 Study comparing Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy Patients with Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy and are at a high risk of recurrence CUH Click Here
SABRE Effectiveness of the SpaceOAR Vue System in Subjects with Prostate Cancer Being Treated with Stereotactic Body Radiotherapy (SABRE) Patients with moderate risk of Prostate Cancer treated with Stereotactic Body Radiotherapy CUH Click Here
LIAM Mc Linking In with Advice and Supports for Men Impacted by Metastatic Cancer (LIAM Mc) Advanced / metastatic genitourinary cancer (including prostate, kidney, urothelial tract, testicular and/or penile cancers) CUH Click
here
PACE
NODES		 Study will look at the safety of curative radiotherapy to the prostate and lymph glands given in 5 visits, in men with high risk localised prostate cancer Patients with high risk localised prostate cancer, deemed suitable for SBRT radiotherapy and planned for 12 – 36 months androgen deprivation therapy BSH Click
here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
R3767-ONC-2011  Study comparing combination of study drugs called Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma  Unresectable Stage III and Stage IV (metastatic) melanoma (AJCC, 8th revised edition) who have not received prior systemic therapy for advanced unresectable disease  CUH Click
here
R2810-ONC-1788  Study comparing drug called Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma  High-risk cutaneous squamous cell carcinoma with Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1  CUH Click Here
R3767-ONC-2055  Study of combination of study drugs called Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma  Patients with Completely Resected High-risk Melanoma  CUH Click Here
Uveal Melanoma Development and characterisation of ex vivo culture models
of metastatic uveal melanoma		 Patients who are diagnosed with uveal melanoma and undergoing surveillance and/or a biopsy procedure for metastatic uveal melanoma  UHW  Available
on request 

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
ENGOT-EN20/ GOG-3083/ XPORT-EC-042   Study to evaluate the efficacy and safety of study drug called Selinexor as a maintenance therapy in patients with endometrial carcinoma (EC)  Patients with endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) after completing at least 12 weeks of platinum-based therapy  CUH

UHW

 Click
here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
PRESERVE  Preservation of Swallowing in Resected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE)  Patients with resected oral cavity squamous cell carcinoma with an indication for post-operative radiation therapy, and at least one pathologically node negative dissected hemi-neck  CUH Click
here

Basket trials are clinical trials which cannot be categorised based on one specific disease category.

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
Microbiome study  To predict response to cancer therapies using microbiome biomarkers  Patient advocates with cancer with life expectancy more than 3 months, with any line of palliative ICI alone or in combination with Tyrosine Kinase Inhibitors (TKI) and/or cytotoxic chemotherapy  BSH Available
on request
SABR-COMET3  Study to compare the effect of Stereotactic Ablative Radiotherapy (SABR), relative to Standard of Care (SOC) alone, on overall survival in patients with controlled primary solid tumours and 1-3 current metastatic cancer lesions.  Patients with oligometastatic disease who have 1 controlled primary solid tumour and 1-3 current metastatic lesions, and a maximum of 8 lifetime metastatic lesions  BSH Click Here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
INDEPENDENCE ACE-536-MF-002  Study to Compare the Efficacy and Safety of a drug called Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions Patients with confirmed Myeloproliferative neoplasm associated Myelofibrosis (MF) and anaemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions CUH Click Here
HOVON 150  Study comparing ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy  Patients with newly diagnosed acute myeloid leukaemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy  CUH Click Here
ANTHOS ANT007 A study Comparing the Effect of Abelacimab to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE Patients with confirmed regionally invasive/ metastatic cancer diagnosed with cancer associated VTE eligible for anticoagulation therapy with DOAC

CUH

BSH

 Click Here
ANTHOS ANT008 A study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE Patients with unresectable, locally advanced, metastatic, or non-metastatic GI/GU cancer with diagnosis of cancer associated VTE eligible for Anticoagulation therapy with LMWH CUH

BSH

 Click Here
Mahogany

(Beigene 311-308)

 Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients with Relapsed/Refractory Follicular or Marginal Zone Lymphoma  Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma  UHW Click Here
AFFIRM-AL  Study comparing combination of drug called birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients  Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis  CUH Click Here
ISA RVD  Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  Patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant  UHW Click Here
Discontinuation Study Discontinuation of Lenalidomide maintenance for the patients diagnosed with multiple myeloma in sustainable Minimal Residual disease (MRD) negative remission without high–risk features  Patients diagnosed with multiple myeloma (MM) without high–risk feature and who have completed at least 2 years on maintenance therapy with lenalidomide  CUH Available
on request
CC-92480-MM-003 (CA057-001)/ SUCCESSOR  Study to evaluate the safety and efficacy of study drugs called mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd)  Participants with multiple myeloma that have not responded well to the treatment/that has come back after the treatment and who have tried between 1 to 3 treatments before, and have used lenalidomide before  CUH Click Here
firmMIND INCMOR0208-305  Evaluate the Safety and Efficacy of combination of drugs called Tafasitamab Plus Lenalidomide in Participants with Diffuse Large B-cell Lymphoma that has come back after the treatment or hasn’t responded to the treatment  Participants with Diffuse Large B-cell Lymphoma that has come back after the treatment or hasn’t responded to the treatment  BSH Click Here
CC-220-MM-002  Study to determine maximum tolerated dose,safety and tolerability, drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma  Participants with Multiple Myeloma  CUH Click Here

Biobanking

A biobank is a facility where biological samples such as blood, tissue, and DNA are stored for research purposes. They aid in advancing medical knowledge and developing new treatments.

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
LYM-MAP The use of cell free DNA in High Grade non-Hodgkin’s lymphoma in conjunction with FDG PET CT scan parameters  All newly diagnosed and relapsed High-Grade non–Hodgkin Lymphoma patients over the age of 16 may be included  CUH Available on request 
BCNI
Biobank 		 Blood Cancer Biobank Ireland (BCBI) sample collection and management  All newly diagnosed CLL (Chronic lymphocytic leukaemia), AML (Acute myeloid leukaemia) and MM (Multiple myeloma) patients who have not yet received any treatment  CUH Click
here

Key Terms

Adjuvant treatment: Adjuvant treatment refers to additional therapy administered following the primary treatment to reduce the risk of cancer recurrence.

Placebo: A placebo is an inert substance or treatment given to individuals in a clinical study to assess the true effects of a specific treatment. It serves as a control to differentiate between the effects of the active treatment and the psychological response of the participants.

Maintenance therapy: Maintenance therapy involves continued treatment after the initial therapy, often at lower doses, to sustain the response achieved and prevent disease progression or recurrence.

Relapse: Relapse is the return of signs and symptoms of a disease after a period of improvement or remission.

Proteomics: Refers to the study of proteins in the body. 

Microbiome: The microbiome refers to all the tiny living organisms, like bacteria, viruses, and fungi, that live in and on our bodies. These microorganisms play a big role in keeping us healthy by helping with digestion, protecting against harmful germs, and even influencing our mood and immune system. 

Menopause: Menopause is when your periods stop due to lower hormone levels. It usually affects women between the ages of 45 and 55, but it can happen earlier. 

If you have questions or queries, please contact the relevant research nurse assigned to each site.

Bons Secours Hospital

Lisa Stacklmstack@bonsecours.ie

Cork University Hospital

Debra O’Hare debrad.ohare@hse.ie

Waterford University Hospital

Flordeliza Calacsan flordeliza.calacsan@hse.ie

Contact Sites

Bons Secours Hospital

Lisa Stack lmstack@bonsecours.ie

021 4542807 ext: 2663

Oncology Clinical Trials Department, Bon Secours Hospital, College Rd, Cork

Cork University Hospital

Debra O’Hare debrad.ohare@hse.ie

021 4234816

Cancer Trials Unit-Glandore Dept, Cork University Hospital Wilton, Cork

Waterford University Hospital

Flordeliza Calacsan flordeliza.calacsan@hse.ie

Lauren Clarke lauren.clarke@hse.ie

Dunmore Road, Waterford City

Cancer Trials Ireland Logo

Where can I find the trials available in Ireland?

Cancer Trials Ireland provides further information about ongoing trials in Ireland.

Learn More

question mark

Thinking of taking part in a clinical trial?

See if you are eligible for a trial, and consider the pros and cons of participating.

Learn More